论文部分内容阅读
依沙佐米(ixazomib)是由日本武田制药研制的新一代蛋白酶体抑制剂,2015年11月美国FDA批准其联合来那度胺以及地塞米松,用于既往已接受过至少一种治疗方案的多发性骨髓瘤(MM)的治疗。作为首个口服蛋白酶体抑制剂,依沙佐米为业界普遍看好,其突破了现有蛋白酶抑制剂无法口服的局限性,对改善患者的生活质量具有重要现实意义。笔者就依沙佐米的基本信息、作用机理、药动学、药效学、临床试验及应用等研发动态作一概述,以期为医院临床用药提供一定的指导。
Ixazomib is a new generation of proteasome inhibitor developed by Japan’s Takeda Pharmaceutical. In November 2015, the United States FDA approved its combination of lenalidomide and dexamethasone for receiving at least one treatment protocol Of multiple myeloma (MM) treatment. As the first oral proteasome inhibitor, it is widely accepted by the industry that it breaks through the limitations of the existing protease inhibitors and can improve the quality of life of patients. The author gives an overview on the basic information, mechanism of action, pharmacokinetics, pharmacodynamics, clinical trials and application of the research on the development of inoxazosin, in order to provide some guidance for clinical medication in the hospital.